{
    "medicine_id": "d5551647b39ef910c62889de1a459b70e2db4c2b",
    "platform_id": "DB06202",
    "metadata": {
        "name": "Fablyn 500 \u03bcg Tablet film coated",
        "composition": "500 \u03bcg Lasofoxifene",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in postmenopausal osteoporosis to reduce the risk of both vertebral and novertebral fractures as well as address other postmenopausal conditions including reduction in risk of breast cancer and treatment of vulvar and vaginal atrophy VVA",
            "contraindications": {
                "disease": "Lasofoxifene increases the risk of venous thromboembolism driven by increased risk of deep vein thrombosis Other adverse effects include hot flushes muscle spasms and vaginal bleeding",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Lasofoxifene exhibits both significant estrogenic and antiestrogenic activity both in vitro and in vivo targeting any tissues that possess ERs such as bone uterus breast blood vessels and liver Binding assays demonstrated high affinity of the compound for both ER\u03b1 and ER\u03b2 in a tissue dependent manner It mimics the effects of estradiol with varying agonist and antagonist effects",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB04938",
                        "description": "The risk or severity of adverse effects can be increased when Lasofoxifene is combined with Ospemifene"
                    },
                    {
                        "drugbank-id": "DB15690",
                        "description": "Lasofoxifene may decrease effectiveness of Fluoroestradiol F 18 as a diagnostic agent"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}